Bioceres price target lowered to $8 from $13 at Lake Street

Lake Street analyst Ben Klieve lowered the firm’s price target on Bioceres (BIOX) to $8 from $13 and keeps a Buy rating on the shares. Preliminary revenue and earnings results were “nowhere near even the low end of consensus” notes the analyst, who looks for material updates on next week’s earnings call for how the company is addressing the underlying challenges that are both internal and external.